Zydus Lifesciences Limited (ZYDUSLIFE) announces USFDA inspection of pharmacovigilance and post marketing system concludes with nil observations.
Zydus Lifesciences Limited (ZYDUSLIFE) announces positive topline results from completed EVIDENCES-X Phase II(b) clinical trial for Saroglitazar Mg in MASH.
Zydus Lifesciences Limited (ZYDUSLIFE) receives final approval from USFDA for Ascorbic Acid Injection, gaining 180-day CGT exclusivity.
Zydus Lifesciences Limited (ZYDUSLIFE) announces a strategic option and license agreement with Mereo BioPharma for alvelestat in Alpha-1 Antitrypsin Deficien.
Zydus Lifesciences Limited (NSE: ZYDUSLIFE) moves up 5% intraday to ₹1177.2, nearing resistance at ₹1195. This move is backed by strong Q1 FY27 revenues.
Zydus Lifesciences Limited (ZYDUSLIFE) reports a 22% YoY revenue surge in Q1 FY27, driven by strong growth in India and North America.
Zydus Lifesciences Limited (ZYDUSLIFE) launches REVAHALE™, India’s first once-daily nebulised LAMA for COPD treatment, offering sustained 24-hour bronchodila.
Zydus Lifesciences Limited (ZYDUSLIFE) secures final approval from USFDA for Indocyanine Green for Injection, triggering 180-day CGT exclusivity.
Zydus Lifesciences Limited (ZYDUSLIFE) receives EIR from USFDA for its injectable facility with Voluntary Action Indicated (VAI) classification.
Zydus Lifesciences Limited (ZYDUSLIFE) gets approval for Phase III trial of Desidustat for sickle cell disease patients.